Review



proteome profiler human apoptosis array kit  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    R&D Systems proteome profiler human apoptosis array kit
    Changes in expression levels of <t>apoptosis-related</t> proteins in T-24 cells following treatment with: curcumin (B); Tw60 : Sp60 : Chol – S4 (C); Tw60 : Sp60 : Chol : HD-PAA 17 – S19 (D), as compared to untreated control (A). Cells were exposed to equieffective concentrations (IC 50 ) of free curcumin and its niosome formulations for 24 h, following which a human <t>proteome</t> profiler assay was performed according to manufacturer's instructions. Further densitometric analysis of the array spots was conducted using ImageJ software and the most prominent changes in the proteome were ex-pressed graphically (E). Legend: 1 – bad; 2 – TRAILR1, 3 – TRAILR2; 4 – bcl-2; 5 – bcl- x ; 6 – fas, CD95; 7 – pro-caspase 3; 8 – HIF-1α; 9 – HMOX1 (antiapoptotic); 10 – cIAP1; 11 – HSP60; 12 – survivin; 13 – claspin; 14 – HSP70; 15 – TNF RI; 16 – XIAP; 17 – HTRA/Omi.
    Proteome Profiler Human Apoptosis Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 300 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/Proteome+Profiler+Human+Apoptosis+Array+Kit/pmc11008427-306-0-6
    Average 96 stars, based on 300 article reviews
    proteome profiler human apoptosis array kit - by Bioz Stars, 2026-11
    96/100 stars

    Images

    1) Product Images from "pH-responsive niosome-based nanocarriers of antineoplastic agents † "

    Article Title: pH-responsive niosome-based nanocarriers of antineoplastic agents †

    Journal: RSC Advances

    doi: 10.1039/d4ra01334d

    Changes in expression levels of apoptosis-related proteins in T-24 cells following treatment with: curcumin (B); Tw60 : Sp60 : Chol – S4 (C); Tw60 : Sp60 : Chol : HD-PAA 17 – S19 (D), as compared to untreated control (A). Cells were exposed to equieffective concentrations (IC 50 ) of free curcumin and its niosome formulations for 24 h, following which a human proteome profiler assay was performed according to manufacturer's instructions. Further densitometric analysis of the array spots was conducted using ImageJ software and the most prominent changes in the proteome were ex-pressed graphically (E). Legend: 1 – bad; 2 – TRAILR1, 3 – TRAILR2; 4 – bcl-2; 5 – bcl- x ; 6 – fas, CD95; 7 – pro-caspase 3; 8 – HIF-1α; 9 – HMOX1 (antiapoptotic); 10 – cIAP1; 11 – HSP60; 12 – survivin; 13 – claspin; 14 – HSP70; 15 – TNF RI; 16 – XIAP; 17 – HTRA/Omi.
    Figure Legend Snippet: Changes in expression levels of apoptosis-related proteins in T-24 cells following treatment with: curcumin (B); Tw60 : Sp60 : Chol – S4 (C); Tw60 : Sp60 : Chol : HD-PAA 17 – S19 (D), as compared to untreated control (A). Cells were exposed to equieffective concentrations (IC 50 ) of free curcumin and its niosome formulations for 24 h, following which a human proteome profiler assay was performed according to manufacturer's instructions. Further densitometric analysis of the array spots was conducted using ImageJ software and the most prominent changes in the proteome were ex-pressed graphically (E). Legend: 1 – bad; 2 – TRAILR1, 3 – TRAILR2; 4 – bcl-2; 5 – bcl- x ; 6 – fas, CD95; 7 – pro-caspase 3; 8 – HIF-1α; 9 – HMOX1 (antiapoptotic); 10 – cIAP1; 11 – HSP60; 12 – survivin; 13 – claspin; 14 – HSP70; 15 – TNF RI; 16 – XIAP; 17 – HTRA/Omi.

    Techniques Used: Expressing, Control, Software

    Changes in expression levels of apoptosis-related proteins in MJ cells following treatment with: curcumin (B); Tw60 : Sp60 : Chol – S4 (C); Tw60 : Sp60 : Ch : HD-PAA 17 – S19 (D), as compared to untreated control (A). Cells were exposed to equieffective concentrations (IC 50 ) of free curcumin and its niosome formulations for 24 h, following which a human proteome profiler assay was performed according to manufacturer's instructions. Further densitometric analysis of the array spots was conducted using ImageJ software and the most prominent changes in the proteome were ex-pressed graphically (E). Legend: 1 – bcl-2; 2 – bcl- x ; 3 – HIF-1α; 4 – phospho p53; 5 – cIAP1; 6 – cIAP2; 7 – survivin; 8 – claspin; 9 – HSP70; 10 – XIAP.
    Figure Legend Snippet: Changes in expression levels of apoptosis-related proteins in MJ cells following treatment with: curcumin (B); Tw60 : Sp60 : Chol – S4 (C); Tw60 : Sp60 : Ch : HD-PAA 17 – S19 (D), as compared to untreated control (A). Cells were exposed to equieffective concentrations (IC 50 ) of free curcumin and its niosome formulations for 24 h, following which a human proteome profiler assay was performed according to manufacturer's instructions. Further densitometric analysis of the array spots was conducted using ImageJ software and the most prominent changes in the proteome were ex-pressed graphically (E). Legend: 1 – bcl-2; 2 – bcl- x ; 3 – HIF-1α; 4 – phospho p53; 5 – cIAP1; 6 – cIAP2; 7 – survivin; 8 – claspin; 9 – HSP70; 10 – XIAP.

    Techniques Used: Expressing, Control, Software

    Changes in expression levels of inflammation-related proteins in T-24 cells following treatment with: curcumin (B); Tw60 : Sp60 : Chol – S4 (C); Tw60 : Sp60 : Ch : HD-PAA 17 – S19 (D), as compared to untreated control (A). Cells were exposed to equieffective concentrations (IC 50 ) of free curcumin and its niosome formulations for 24 h, following which a human cytokine profiler assay was performed according to manufacturer instructions. Further densitometric analysis of the array spots was conducted using ImageJ software and the most prominent changes in the proteome were expressed graphically (E). Legend: 1 – MIF; 2 – PAI1; 3 – G-CSF; 4 – ICAM-1; 5 – IL-6; 6 – IL-18; 7 – IL-8; 8 – CXCL1; 9 – IL-1α; 10 – IL-1β.
    Figure Legend Snippet: Changes in expression levels of inflammation-related proteins in T-24 cells following treatment with: curcumin (B); Tw60 : Sp60 : Chol – S4 (C); Tw60 : Sp60 : Ch : HD-PAA 17 – S19 (D), as compared to untreated control (A). Cells were exposed to equieffective concentrations (IC 50 ) of free curcumin and its niosome formulations for 24 h, following which a human cytokine profiler assay was performed according to manufacturer instructions. Further densitometric analysis of the array spots was conducted using ImageJ software and the most prominent changes in the proteome were expressed graphically (E). Legend: 1 – MIF; 2 – PAI1; 3 – G-CSF; 4 – ICAM-1; 5 – IL-6; 6 – IL-18; 7 – IL-8; 8 – CXCL1; 9 – IL-1α; 10 – IL-1β.

    Techniques Used: Expressing, Control, Software

    Changes in expression levels of inflammation-related proteins in MJ cells following treatment with: curcumin (B); Tw60 : Sp60 : Ch – S4 (C); Tw60 : Sp60 : Ch : PAA 17 – S19 (D), as compared to untreated control (A). Cells were exposed to equieffective concentrations (IC 50 ) of free curcumin and its niosome formulations for 24 h, following which a human cytokine profiler assay was performed according to manufacturer instructions. Further densitometric analysis of the array spots was conducted using ImageJ software and the most prominent changes in the proteome were expressed graphically (E). Legend: 1 – CCL2/MCP-1; 2 – CXCL11/I-TAC; 3 – CXCL12/SDF-1; 4 – IL-13; 5 – IL-16; 6 – MIF; 7 – SERPIN E1/PAI-1; 8 – CCL5/RANTES; 9 – GM-CSF; 10 – IL-5; 11 – ICAM1/CD54; 12 – IL-6; 13 – IL-18; 14 – IL-21; 15 – IL-1α; 16 – IL-32α.
    Figure Legend Snippet: Changes in expression levels of inflammation-related proteins in MJ cells following treatment with: curcumin (B); Tw60 : Sp60 : Ch – S4 (C); Tw60 : Sp60 : Ch : PAA 17 – S19 (D), as compared to untreated control (A). Cells were exposed to equieffective concentrations (IC 50 ) of free curcumin and its niosome formulations for 24 h, following which a human cytokine profiler assay was performed according to manufacturer instructions. Further densitometric analysis of the array spots was conducted using ImageJ software and the most prominent changes in the proteome were expressed graphically (E). Legend: 1 – CCL2/MCP-1; 2 – CXCL11/I-TAC; 3 – CXCL12/SDF-1; 4 – IL-13; 5 – IL-16; 6 – MIF; 7 – SERPIN E1/PAI-1; 8 – CCL5/RANTES; 9 – GM-CSF; 10 – IL-5; 11 – ICAM1/CD54; 12 – IL-6; 13 – IL-18; 14 – IL-21; 15 – IL-1α; 16 – IL-32α.

    Techniques Used: Expressing, Control, Software

    Related Articles

    other:

    Article Title: Differential Effects of Olive Leaf Extract on Human Small and Non-Small Cell Lung Cancer and Synergy with Cisplatin: Rationale for Its Potential Use as Food Supplement for Patients?
    Article Snippet: Infinite 200 pro Bioreader (absorbance at 555 nm). Four or six hundred µgs of each protein lysate were assessed on 2 different human proteome profiler kits following the manufacturer’s instructions (Biotechne, Minneapolis, MN, USA): (i) apoptosis array (Cat#ARY009, lot P508387) detecting the relative levels of expression of 35 apoptosis-related proteins, and (ii) phospho-kinase array (Cat#ARY003C,



    Similar Products

    90
    Eve Technologies Corporation human high sensitivity t-cell discovery array 14-plex (hdhstc14
    Human High Sensitivity T Cell Discovery Array 14 Plex (Hdhstc14, supplied by Eve Technologies Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/human+high+sensitivity+t+cell+discovery+array+14+plex++hdhstc14/nct05806385-145-18-10
    Average 90 stars, based on 1 article reviews
    human high sensitivity t-cell discovery array 14-plex (hdhstc14 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    96
    R&D Systems proteome profiler human cytokine array kit
    Proteome Profiler Human Cytokine Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/Proteome+Profiler+Human+Cytokine+Array+Kit/pm42977769-893-13-19
    Average 96 stars, based on 1 article reviews
    proteome profiler human cytokine array kit - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    93
    R&D Systems proteome profiler human cell stress array kit
    Proteome Profiler Human Cell Stress Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/Proteome+Profiler+Human+Cell+Stress+Array+Kit/pmc13754587-487-35-42
    Average 93 stars, based on 1 article reviews
    proteome profiler human cell stress array kit - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    96
    R&D Systems proteome profiler human phospho kinase array kit
    Proteome Profiler Human Phospho Kinase Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/Proteome+Profiler+Human+Phospho-Kinase+Array+Kit/pmc13754587-487-27-33
    Average 96 stars, based on 1 article reviews
    proteome profiler human phospho kinase array kit - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    95
    RayBiotech inc human cytokine antibody array
    Human Cytokine Antibody Array, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/Human+Cytokine+Array+Q9/pm42989007-291-28-27
    Average 95 stars, based on 1 article reviews
    human cytokine antibody array - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    97
    RayBiotech inc human cytokine array c5 membrane kit
    (A) Schematic of the generation of synovium-on-a-chip models using synovial tissue and blood samples from patients with RA or osteoarthritis (OA) for comparative assessment of disease-associated phenotypes. (B) Representative immunofluorescence images and quantification of collagen IV deposition in RA and OA chips on days 3, 6, and 9 (n = 3 chips per condition per time point; Comparisons between RA and OA chips at each time point were performed using two-tailed unpaired Welch’s t-tests with Šídák correction for three comparisons; P values indicated). Scale bar, 50 μm. (C) Heatmap showing secretion profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in OA and RA chip culture medium pooled from 3 independently cultured chips on day 12. Color scale indicates log₁₀-transformed relative secretion values. (D) Quantification of Ki67⁺ lining FLS. Each dot represents the mean value for one chip (n = 3 chips; two-tailed unpaired t-test; P < 0.0001). (E) Representative immune cell migration trajectories and quantification of migration distance in RA and OA chips (three technical replicates with >45 immune cells per condition, two-tailed unpaired t-test, P <0.0001) (F) Quantification of the HLA-DR/CD163 ratio as an indicator of macrophage polarization (n = 3 chips per condition). (G) Temporal profiles of IL-6 concentrations in culture medium collected from RA and OA chips on days 4, 6, 8, 10, and 12 (n = 3 chips per condition per time point). IL-6 concentrations on day 12 were compared between RA and OA chips using a two-tailed unpaired t-test (P = 0.0058). (H) Multiplex profiling of cytokines associated with inflammation, immune regulation, chemotaxis, and growth in RA and OA chips on day 12. Each dot represents one patient, measured using culture medium pooled from 3 independently cultured chips; 2 patients were analyzed per group. Horizontal lines indicate group means. Values represent log₁₀-transformed relative <t>cytokine</t> secretion. Bars and error bars in (B), (D–G) indicate mean ± SD.
    Human Cytokine Array C5 Membrane Kit, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/Human+Cytokine+Array+C5/bio_rxiv__64898__2026__10__30__763140-282-7-15
    Average 97 stars, based on 1 article reviews
    human cytokine array c5 membrane kit - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    91
    RayBiotech inc mmp secretion
    (A) Schematic of the generation of synovium-on-a-chip models using synovial tissue and blood samples from patients with RA or osteoarthritis (OA) for comparative assessment of disease-associated phenotypes. (B) Representative immunofluorescence images and quantification of collagen IV deposition in RA and OA chips on days 3, 6, and 9 (n = 3 chips per condition per time point; Comparisons between RA and OA chips at each time point were performed using two-tailed unpaired Welch’s t-tests with Šídák correction for three comparisons; P values indicated). Scale bar, 50 μm. (C) Heatmap showing secretion profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in OA and RA chip culture medium pooled from 3 independently cultured chips on day 12. Color scale indicates log₁₀-transformed relative secretion values. (D) Quantification of Ki67⁺ lining FLS. Each dot represents the mean value for one chip (n = 3 chips; two-tailed unpaired t-test; P < 0.0001). (E) Representative immune cell migration trajectories and quantification of migration distance in RA and OA chips (three technical replicates with >45 immune cells per condition, two-tailed unpaired t-test, P <0.0001) (F) Quantification of the HLA-DR/CD163 ratio as an indicator of macrophage polarization (n = 3 chips per condition). (G) Temporal profiles of IL-6 concentrations in culture medium collected from RA and OA chips on days 4, 6, 8, 10, and 12 (n = 3 chips per condition per time point). IL-6 concentrations on day 12 were compared between RA and OA chips using a two-tailed unpaired t-test (P = 0.0058). (H) Multiplex profiling of cytokines associated with inflammation, immune regulation, chemotaxis, and growth in RA and OA chips on day 12. Each dot represents one patient, measured using culture medium pooled from 3 independently cultured chips; 2 patients were analyzed per group. Horizontal lines indicate group means. Values represent log₁₀-transformed relative <t>cytokine</t> secretion. Bars and error bars in (B), (D–G) indicate mean ± SD.
    Mmp Secretion, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/Human+MMP+Array+C1/bio_rxiv__64898__2026__10__30__763140-284-0-11
    Average 91 stars, based on 1 article reviews
    mmp secretion - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    90
    Thermo Fisher human exon 1.0st array
    (A) Schematic of the generation of synovium-on-a-chip models using synovial tissue and blood samples from patients with RA or osteoarthritis (OA) for comparative assessment of disease-associated phenotypes. (B) Representative immunofluorescence images and quantification of collagen IV deposition in RA and OA chips on days 3, 6, and 9 (n = 3 chips per condition per time point; Comparisons between RA and OA chips at each time point were performed using two-tailed unpaired Welch’s t-tests with Šídák correction for three comparisons; P values indicated). Scale bar, 50 μm. (C) Heatmap showing secretion profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in OA and RA chip culture medium pooled from 3 independently cultured chips on day 12. Color scale indicates log₁₀-transformed relative secretion values. (D) Quantification of Ki67⁺ lining FLS. Each dot represents the mean value for one chip (n = 3 chips; two-tailed unpaired t-test; P < 0.0001). (E) Representative immune cell migration trajectories and quantification of migration distance in RA and OA chips (three technical replicates with >45 immune cells per condition, two-tailed unpaired t-test, P <0.0001) (F) Quantification of the HLA-DR/CD163 ratio as an indicator of macrophage polarization (n = 3 chips per condition). (G) Temporal profiles of IL-6 concentrations in culture medium collected from RA and OA chips on days 4, 6, 8, 10, and 12 (n = 3 chips per condition per time point). IL-6 concentrations on day 12 were compared between RA and OA chips using a two-tailed unpaired t-test (P = 0.0058). (H) Multiplex profiling of cytokines associated with inflammation, immune regulation, chemotaxis, and growth in RA and OA chips on day 12. Each dot represents one patient, measured using culture medium pooled from 3 independently cultured chips; 2 patients were analyzed per group. Horizontal lines indicate group means. Values represent log₁₀-transformed relative <t>cytokine</t> secretion. Bars and error bars in (B), (D–G) indicate mean ± SD.
    Human Exon 1.0st Array, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/nct04134260-8-18--1
    Average 90 stars, based on 1 article reviews
    human exon 1.0st array - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    95
    R&D Systems human chemokine array kit
    (A) Schematic of the generation of synovium-on-a-chip models using synovial tissue and blood samples from patients with RA or osteoarthritis (OA) for comparative assessment of disease-associated phenotypes. (B) Representative immunofluorescence images and quantification of collagen IV deposition in RA and OA chips on days 3, 6, and 9 (n = 3 chips per condition per time point; Comparisons between RA and OA chips at each time point were performed using two-tailed unpaired Welch’s t-tests with Šídák correction for three comparisons; P values indicated). Scale bar, 50 μm. (C) Heatmap showing secretion profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in OA and RA chip culture medium pooled from 3 independently cultured chips on day 12. Color scale indicates log₁₀-transformed relative secretion values. (D) Quantification of Ki67⁺ lining FLS. Each dot represents the mean value for one chip (n = 3 chips; two-tailed unpaired t-test; P < 0.0001). (E) Representative immune cell migration trajectories and quantification of migration distance in RA and OA chips (three technical replicates with >45 immune cells per condition, two-tailed unpaired t-test, P <0.0001) (F) Quantification of the HLA-DR/CD163 ratio as an indicator of macrophage polarization (n = 3 chips per condition). (G) Temporal profiles of IL-6 concentrations in culture medium collected from RA and OA chips on days 4, 6, 8, 10, and 12 (n = 3 chips per condition per time point). IL-6 concentrations on day 12 were compared between RA and OA chips using a two-tailed unpaired t-test (P = 0.0058). (H) Multiplex profiling of cytokines associated with inflammation, immune regulation, chemotaxis, and growth in RA and OA chips on day 12. Each dot represents one patient, measured using culture medium pooled from 3 independently cultured chips; 2 patients were analyzed per group. Horizontal lines indicate group means. Values represent log₁₀-transformed relative <t>cytokine</t> secretion. Bars and error bars in (B), (D–G) indicate mean ± SD.
    Human Chemokine Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/Proteome+Profiler+Human+Chemokine+Array+Kit/pmc13761396-66-1-6
    Average 95 stars, based on 1 article reviews
    human chemokine array kit - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    96
    R&D Systems proteome profiler human xl cytokine array kit
    (A) Schematic of the generation of synovium-on-a-chip models using synovial tissue and blood samples from patients with RA or osteoarthritis (OA) for comparative assessment of disease-associated phenotypes. (B) Representative immunofluorescence images and quantification of collagen IV deposition in RA and OA chips on days 3, 6, and 9 (n = 3 chips per condition per time point; Comparisons between RA and OA chips at each time point were performed using two-tailed unpaired Welch’s t-tests with Šídák correction for three comparisons; P values indicated). Scale bar, 50 μm. (C) Heatmap showing secretion profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in OA and RA chip culture medium pooled from 3 independently cultured chips on day 12. Color scale indicates log₁₀-transformed relative secretion values. (D) Quantification of Ki67⁺ lining FLS. Each dot represents the mean value for one chip (n = 3 chips; two-tailed unpaired t-test; P < 0.0001). (E) Representative immune cell migration trajectories and quantification of migration distance in RA and OA chips (three technical replicates with >45 immune cells per condition, two-tailed unpaired t-test, P <0.0001) (F) Quantification of the HLA-DR/CD163 ratio as an indicator of macrophage polarization (n = 3 chips per condition). (G) Temporal profiles of IL-6 concentrations in culture medium collected from RA and OA chips on days 4, 6, 8, 10, and 12 (n = 3 chips per condition per time point). IL-6 concentrations on day 12 were compared between RA and OA chips using a two-tailed unpaired t-test (P = 0.0058). (H) Multiplex profiling of cytokines associated with inflammation, immune regulation, chemotaxis, and growth in RA and OA chips on day 12. Each dot represents one patient, measured using culture medium pooled from 3 independently cultured chips; 2 patients were analyzed per group. Horizontal lines indicate group means. Values represent log₁₀-transformed relative <t>cytokine</t> secretion. Bars and error bars in (B), (D–G) indicate mean ± SD.
    Proteome Profiler Human Xl Cytokine Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/Proteome+Profiler+Human+XL+Cytokine+Array+Kit/pm42956987-451-13-21
    Average 96 stars, based on 1 article reviews
    proteome profiler human xl cytokine array kit - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    Image Search Results


    (A) Schematic of the generation of synovium-on-a-chip models using synovial tissue and blood samples from patients with RA or osteoarthritis (OA) for comparative assessment of disease-associated phenotypes. (B) Representative immunofluorescence images and quantification of collagen IV deposition in RA and OA chips on days 3, 6, and 9 (n = 3 chips per condition per time point; Comparisons between RA and OA chips at each time point were performed using two-tailed unpaired Welch’s t-tests with Šídák correction for three comparisons; P values indicated). Scale bar, 50 μm. (C) Heatmap showing secretion profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in OA and RA chip culture medium pooled from 3 independently cultured chips on day 12. Color scale indicates log₁₀-transformed relative secretion values. (D) Quantification of Ki67⁺ lining FLS. Each dot represents the mean value for one chip (n = 3 chips; two-tailed unpaired t-test; P < 0.0001). (E) Representative immune cell migration trajectories and quantification of migration distance in RA and OA chips (three technical replicates with >45 immune cells per condition, two-tailed unpaired t-test, P <0.0001) (F) Quantification of the HLA-DR/CD163 ratio as an indicator of macrophage polarization (n = 3 chips per condition). (G) Temporal profiles of IL-6 concentrations in culture medium collected from RA and OA chips on days 4, 6, 8, 10, and 12 (n = 3 chips per condition per time point). IL-6 concentrations on day 12 were compared between RA and OA chips using a two-tailed unpaired t-test (P = 0.0058). (H) Multiplex profiling of cytokines associated with inflammation, immune regulation, chemotaxis, and growth in RA and OA chips on day 12. Each dot represents one patient, measured using culture medium pooled from 3 independently cultured chips; 2 patients were analyzed per group. Horizontal lines indicate group means. Values represent log₁₀-transformed relative cytokine secretion. Bars and error bars in (B), (D–G) indicate mean ± SD.

    Journal: bioRxiv

    Article Title: Patient-Derived Synovium-on-a-Chip Recapitulates Disease and Treatment Response and Permits Study of Resistance in Rheumatoid Arthritis

    doi: 10.64898/2026.10.30.763140

    Figure Lengend Snippet: (A) Schematic of the generation of synovium-on-a-chip models using synovial tissue and blood samples from patients with RA or osteoarthritis (OA) for comparative assessment of disease-associated phenotypes. (B) Representative immunofluorescence images and quantification of collagen IV deposition in RA and OA chips on days 3, 6, and 9 (n = 3 chips per condition per time point; Comparisons between RA and OA chips at each time point were performed using two-tailed unpaired Welch’s t-tests with Šídák correction for three comparisons; P values indicated). Scale bar, 50 μm. (C) Heatmap showing secretion profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in OA and RA chip culture medium pooled from 3 independently cultured chips on day 12. Color scale indicates log₁₀-transformed relative secretion values. (D) Quantification of Ki67⁺ lining FLS. Each dot represents the mean value for one chip (n = 3 chips; two-tailed unpaired t-test; P < 0.0001). (E) Representative immune cell migration trajectories and quantification of migration distance in RA and OA chips (three technical replicates with >45 immune cells per condition, two-tailed unpaired t-test, P <0.0001) (F) Quantification of the HLA-DR/CD163 ratio as an indicator of macrophage polarization (n = 3 chips per condition). (G) Temporal profiles of IL-6 concentrations in culture medium collected from RA and OA chips on days 4, 6, 8, 10, and 12 (n = 3 chips per condition per time point). IL-6 concentrations on day 12 were compared between RA and OA chips using a two-tailed unpaired t-test (P = 0.0058). (H) Multiplex profiling of cytokines associated with inflammation, immune regulation, chemotaxis, and growth in RA and OA chips on day 12. Each dot represents one patient, measured using culture medium pooled from 3 independently cultured chips; 2 patients were analyzed per group. Horizontal lines indicate group means. Values represent log₁₀-transformed relative cytokine secretion. Bars and error bars in (B), (D–G) indicate mean ± SD.

    Article Snippet: Qualitative cytokine profiles were assessed using a Human Cytokine Array C5 membrane kit (catalogue AAH-CYT-5-8, RayBiotech) according to the manufacturer’s protocol.

    Techniques: Tissue, Blood/Plasma/Serum Samples, Immunofluorescence, Two Tailed Test, Cell Culture, Transformation Assay, Immune Cell, Migration, Multiplex Assay, Profiling, Chemotaxis Assay

    (A) Workflow for treatment prediction using patient-derived RA synovium-on-a-chip. Patient-derived chips were subjected to parallel drug perturbation with tocilizumab (IL-6 receptor antagonist, IL-6Ra), infliximab (TNF inhibitor, TNFi) and tofacitinib (JAK inhibitor, JAKi). Four functional readouts were quantified: stromal (ECM remodeling), cytokine (IL-6 secretion), immune (CD45⁺ cell count) and recruitment (immune cell migration distance). Treatment-induced changes relative to matched untreated controls were calculated as fold changes (treated/untreated), standardized within each patient across the three drug treatments (IL-6Ra, TNFi and JAKi), and combined into a composite on-chip response score to predict therapeutic outcome; the four features are also displayed as radar plots for visualization. (B) Heatmap of treatment-induced changes in the four readouts across nine patients and three drug conditions per patient. Rows represent patients, and columns represent readout–treatment combinations. Colors indicate standardized treatment-induced changes, with red indicating increases and blue indicating decreases. Patients were hierarchically clustered using unsupervised Ward’s linkage (ward.D2). Top annotations indicate on-chip treatment; right annotations indicate clinical response history to TNFi and JAKi treatment. Each value represents the mean of 3 chips per condition. (C) Composite treatment response score (mean of the four z-score–normalized readouts) quantified for each patient across IL-6Ra, TNFi and JAKi treatments, demonstrating patient-specific and drug-specific variation in composite response magnitude. (D) Correlation the composite on-chip response score for the clinically matched treatment and clinical improvement measured as ΔDAS28–ESR. Six matched patient–treatment observations from 5 independent patients are shown. Circles indicate TNFi and diamonds indicate JAKi treatment. Pearson r = 0.844, P = 0.0348; Spearman ρ = 0.943, P = 0.0167; both tests were two-tailed. The line represents the fitted linear regression (y = 3.444x + 0.505), and the shaded band indicates 95% confidence interval of the fit. (E) Feature contribution to prediction assessed by LOOCV root mean square error (RMSE) for individual features (migration distance, IL-6, collagen IV and CD45⁺ count, grey), integrated composite score (red) and clinical predictors (baseline DAS28 and JIS-defined inflammatory endotype, blue). The dashed line shows the null model baseline; The integrated composite score achieved the lowest RMSE. The asterisk denotes a prediction error significantly lower than expected by chance for the composite score (permutation test, p = 0.021). (F) Chip-based predicted treatment-response categories across nine patients and three drug conditions. Composite on-chip scores were converted into predicted ΔDAS28–ESR values using the regression model in panel D and classified as good, moderate, or no response according to clinical standard (Good: ΔDAS28–ESR>1.2; Moderate: 0.6 <ΔDAS28– ESR ≤ 1.2; No response: ΔDAS28–ESR ≤ 0.6). Green, yellow, and gray indicate the respective predicted categories.

    Journal: bioRxiv

    Article Title: Patient-Derived Synovium-on-a-Chip Recapitulates Disease and Treatment Response and Permits Study of Resistance in Rheumatoid Arthritis

    doi: 10.64898/2026.10.30.763140

    Figure Lengend Snippet: (A) Workflow for treatment prediction using patient-derived RA synovium-on-a-chip. Patient-derived chips were subjected to parallel drug perturbation with tocilizumab (IL-6 receptor antagonist, IL-6Ra), infliximab (TNF inhibitor, TNFi) and tofacitinib (JAK inhibitor, JAKi). Four functional readouts were quantified: stromal (ECM remodeling), cytokine (IL-6 secretion), immune (CD45⁺ cell count) and recruitment (immune cell migration distance). Treatment-induced changes relative to matched untreated controls were calculated as fold changes (treated/untreated), standardized within each patient across the three drug treatments (IL-6Ra, TNFi and JAKi), and combined into a composite on-chip response score to predict therapeutic outcome; the four features are also displayed as radar plots for visualization. (B) Heatmap of treatment-induced changes in the four readouts across nine patients and three drug conditions per patient. Rows represent patients, and columns represent readout–treatment combinations. Colors indicate standardized treatment-induced changes, with red indicating increases and blue indicating decreases. Patients were hierarchically clustered using unsupervised Ward’s linkage (ward.D2). Top annotations indicate on-chip treatment; right annotations indicate clinical response history to TNFi and JAKi treatment. Each value represents the mean of 3 chips per condition. (C) Composite treatment response score (mean of the four z-score–normalized readouts) quantified for each patient across IL-6Ra, TNFi and JAKi treatments, demonstrating patient-specific and drug-specific variation in composite response magnitude. (D) Correlation the composite on-chip response score for the clinically matched treatment and clinical improvement measured as ΔDAS28–ESR. Six matched patient–treatment observations from 5 independent patients are shown. Circles indicate TNFi and diamonds indicate JAKi treatment. Pearson r = 0.844, P = 0.0348; Spearman ρ = 0.943, P = 0.0167; both tests were two-tailed. The line represents the fitted linear regression (y = 3.444x + 0.505), and the shaded band indicates 95% confidence interval of the fit. (E) Feature contribution to prediction assessed by LOOCV root mean square error (RMSE) for individual features (migration distance, IL-6, collagen IV and CD45⁺ count, grey), integrated composite score (red) and clinical predictors (baseline DAS28 and JIS-defined inflammatory endotype, blue). The dashed line shows the null model baseline; The integrated composite score achieved the lowest RMSE. The asterisk denotes a prediction error significantly lower than expected by chance for the composite score (permutation test, p = 0.021). (F) Chip-based predicted treatment-response categories across nine patients and three drug conditions. Composite on-chip scores were converted into predicted ΔDAS28–ESR values using the regression model in panel D and classified as good, moderate, or no response according to clinical standard (Good: ΔDAS28–ESR>1.2; Moderate: 0.6 <ΔDAS28– ESR ≤ 1.2; No response: ΔDAS28–ESR ≤ 0.6). Green, yellow, and gray indicate the respective predicted categories.

    Article Snippet: Qualitative cytokine profiles were assessed using a Human Cytokine Array C5 membrane kit (catalogue AAH-CYT-5-8, RayBiotech) according to the manufacturer’s protocol.

    Techniques: Derivative Assay, Functional Assay, Cell Characterization, Immune Cell, Migration, Two Tailed Test